Is Medplus Health overvalued or undervalued?

As of 1 July 2025, the valuation grade for Medplus Health has moved from very attractive to attractive. The company is currently considered overvalued. Key ratios indicate this, with a PE ratio of 70.87, an EV to EBITDA ratio of 23.42, and a PEG ratio of 0.55.
In comparison to its peers, Medplus Health's PE ratio is notably lower than Avenue Supermart's 106.99 and Trent's 141.14, both categorized as very expensive. Despite this, Medplus's high valuation metrics suggest it is trading at a premium relative to its earnings potential. Additionally, while Medplus has outperformed the Sensex over the past year with a return of 29.53% compared to the Sensex's 5.31%, the overall valuation indicates that the stock may not be a compelling buy at current levels.